share_log

HOOKIPA Pharma | 3: Initial statement of beneficial ownership of securities-Officer Winderlich Mark

HOOKIPA Pharma | 3: Initial statement of beneficial ownership of securities

HOOKIPA Pharma | 3：首次持股声明
美股SEC公告 ·  04/11 16:21
Moomoo AI 已提取核心信息
Mark Winderlich, the Chief Development Officer of HOOKIPA Pharma Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3 requirements. The filing, dated April 1, 2024, indicates that Winderlich does not beneficially own any non-derivative or derivative securities of the company. The form, signed by attorney-in-fact Reinhard Kandera, was completed on April 11, 2024. This standard disclosure is in compliance with Section 16(a) of the Securities Exchange Act of 1934 and is a routine filing for officers of publicly traded companies.
Mark Winderlich, the Chief Development Officer of HOOKIPA Pharma Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3 requirements. The filing, dated April 1, 2024, indicates that Winderlich does not beneficially own any non-derivative or derivative securities of the company. The form, signed by attorney-in-fact Reinhard Kandera, was completed on April 11, 2024. This standard disclosure is in compliance with Section 16(a) of the Securities Exchange Act of 1934 and is a routine filing for officers of publicly traded companies.
根据表格3的要求，HOOKIPA Pharma Inc. 的首席开发官马克·温德利希已向美国证券交易委员会提交了初步的证券实益所有权声明。该文件日期为2024年4月1日，表明温德利希不以实益方式拥有该公司的任何非衍生或衍生证券。该表格由事实上的律师莱因哈德·坎德拉签署，于2024年4月11日完成。该标准披露符合1934年《证券交易法》第16（a）条，是上市公司高管的例行申报。
根据表格3的要求，HOOKIPA Pharma Inc. 的首席开发官马克·温德利希已向美国证券交易委员会提交了初步的证券实益所有权声明。该文件日期为2024年4月1日，表明温德利希不以实益方式拥有该公司的任何非衍生或衍生证券。该表格由事实上的律师莱因哈德·坎德拉签署，于2024年4月11日完成。该标准披露符合1934年《证券交易法》第16（a）条，是上市公司高管的例行申报。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息